Adheris Health (AHE) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
Meeting opened with confirmation of quorum, introduction of board members and auditors, and CEO John Ciccio outlined a focus on patient engagement and technology-driven solutions.
Format included Chair's address, formal business, and a business update from the CEO.
Financial performance review
FY25 revenue was AUD 63 million, down 36% year-over-year, with gross profit at AUD 32.9 million and a gross margin of 52.3%.
EBITDA loss was AUD 10.7 million, a decline of AUD 13.9 million from the previous year.
A non-cash impairment of AUD 46.5 million was recognized on US intangible assets, driving a substantial statutory loss.
Cost reduction program achieved a 13% decrease in operating costs year over year.
Ended September with net cash of AUD 13 million, excluding AUD 8 million held back from the ANZ divestiture.
Board and executive committee updates
Board reduced from nine to four directors to align with the downsized business.
CFO Sean Slattery appointed as Executive Director.
CEO transition from Rick Ratliff to John Ciccio, who brings over 12 years of experience in the U.S. business.
Latest events from Adheris Health
- Revenue and profit fell 49%+, but FY25 guidance and liquidity are supported by new capital.AHE
Q3 202529 May 2026 - Revenue fell 24% but margin gains and cost-saving transformation support future growth.AHE
H1 202529 May 2026 - Inaugural profit and 24.6% revenue growth drive a bold 5-year expansion plan.AHE
H2 202429 May 2026 - Revenue fell 36% year-over-year as US operations struggled, with ANZ business divested post-period.AHE
H2 202529 May 2026 - Net profit rose to $7.35M on ANZ sale gains, despite revenue drop; focus shifts to US digital growth.AHE
H1 202629 May 2026 - Revenue and profit fell, but cost cuts and digital growth support a Q4 cashflow break-even target.AHE
Q3 202629 Apr 2026 - Revenue down 45.8% year-over-year; cost cuts and new tech platform target recovery.AHE
Q2 20268 Mar 2026 - Record profit, robust growth, and a five-year plan with strategic review to unlock value.AHE
AGM 202414 Jan 2026 - Revenue down 39% on US vaccine delays; margin and 2H outlook improve with cost savings ahead.AHE
Q2 20259 Jan 2026